×

Mathematical modeling of continuous and intermittent androgen suppression for the treatment of advanced prostate cancer. (English) Zbl 1366.92066

Summary: Prostate cancer is one of the most prevalent types of cancer among men. It is stimulated by the androgens, or male sexual hormones, which circulate in the blood and diffuse into the tissue where they stimulate the prostate tumor to grow. One of the most important treatments for advanced prostate cancer has become androgen deprivation therapy (ADT). In this paper we present three different models of ADT for prostate cancer: continuous androgen suppression (CAS), intermittent androgen suppression (IAS), and periodic androgen suppression. Currently, many patients in the U.S. receive CAS therapy of ADT, but many undergo a relapse after several years and experience adverse side effects while receiving treatment. Some clinical studies have introduced various IAS regimens in order to delay the time to relapse, and/or to reduce the economic costs and adverse side effects. We will compute and analyze parameter sensitivity analysis for CAS and IAS which may give insight to plan effective data collection in a future clinical trial. Moreover, a periodic model for IAS is used to develop an analytical formulation for relapse times which then provides information about the sensitivity of relapse to the parameters in our models.

MSC:

92C50 Medical applications (general)
34C60 Qualitative investigation and simulation of ordinary differential equation models
Full Text: DOI

References:

[1] P.-A. Abrahamsson, Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: A systematic review of the literature,, European Urology, 57, 49 (2010) · doi:10.1016/j.eururo.2009.07.049
[2] H. T. Banks, Sensitivity functions and their uses in inverse problems,, J. Inverse Ill-Posed Probl., 15, 683 (2007) · Zbl 1141.34049 · doi:10.1515/jiip.2007.038
[3] H. T. Banks, A parameter sensitivity methodology in the context of HIV delay equation models,, J. Math. Biol., 50, 607 (2005) · Zbl 1083.92025 · doi:10.1007/s00285-004-0299-x
[4] N. C. Buchan, Intermittent androgen suppression for prostate cancer,, Nature Reviews Urology, 7, 552 (2010) · doi:10.1038/nrurol.2010.141
[5] N. Chitnis, Determining important parameters in the spread of malaria through the sensitivity analysis of a mathematical model,, Bull. Math. Biol., 70, 1272 (2008) · Zbl 1142.92025 · doi:10.1007/s11538-008-9299-0
[6] R. A. Everett, Can mathematical models predict the outcomes of prostate cancer patients undergoing intermittent androgen deprivation therapy?,, Biophys. Rev. Lett., 9, 139 (2014) · doi:10.1142/9789814730266_0009
[7] J. K. Hale, <em>Ordinary Differential Equations, \(2^{nd}\) edition,</em>, Krieger Publishing (1980) · Zbl 0433.34003
[8] Y. Hirata, Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer,, J. Theor. Biol., 264, 517 (2010) · Zbl 1406.92304 · doi:10.1016/j.jtbi.2010.02.027
[9] A. M. Ideta, A mathematical model of intermittent androgen suppression for prostate cancer,, J. Nonlinear Sci., 18, 593 (2008) · Zbl 1172.92021 · doi:10.1007/s00332-008-9031-0
[10] H. Lepor, LHRH agonists for the treatment of prostate cancer: 2012,, Reviews in Urology, 14, 1 (2012)
[11] <em>Prostate cancer treatment (PDQ) - Patient Version</em>, National Cancer Institute,, 2016. Available from: <a href=
[12] T. Portz, A clinical data validated mathematical model of prostate cancer growth under intermittent androgen suppression therapy,, AIP Advances, 2, 1 (2012) · doi:10.1063/1.3697848
[13] M. H. Rashid, Intermittent androgen deprivation therapy for prostate cancer,, The Oncologist, 9, 295 (2004) · doi:10.1634/theoncologist.9-3-295
[14] F. G. Rick, Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer,, Urologic Oncology: Seminars and Original Investigations, 33, 270 (2015) · doi:10.1016/j.urolonc.2014.11.006
[15] A. Sciarra, Intermittent androgen-depravation therapy in prostate cancer: a critical review focused on phase 3 trials,, European Urology, 64, 722 (2013)
[16] L. G. Stanley, Sensitivity equation methods for parameter dependent elliptic equations,, Numer. Funct. Anal. Optim., 22, 721 (2001) · Zbl 0996.65121 · doi:10.1081/NFA-100105315
[17] Y. Suzuki, A new protocol for intermittent androgen suppresion therapy of prostate cancer with unstable saddle-point dynamics,, J. Theor. Biol., 350, 1 (2014) · Zbl 1412.92162 · doi:10.1016/j.jtbi.2014.02.004
[18] G. Tanaka, Analysis on a hybrid systems model of intermittent hormonal therapy for prostate cancer,, Physica D, 237, 2616 (2008) · Zbl 1157.37024 · doi:10.1016/j.physd.2008.03.044
[19] F. Verhulst, <em>Nonlinear Differential Equations and Dynamical Systems</em>,, \(2^{nd}\) edition (1996) · Zbl 0854.34002 · doi:10.1007/978-3-642-61453-8
[20] L. Voth, <em>The Exploration and Computations of Mathematical Models of Intermittent Treatment for Prostate Cancer</em>,, M.S. thesis (2012)
This reference list is based on information provided by the publisher or from digital mathematics libraries. Its items are heuristically matched to zbMATH identifiers and may contain data conversion errors. In some cases that data have been complemented/enhanced by data from zbMATH Open. This attempts to reflect the references listed in the original paper as accurately as possible without claiming completeness or a perfect matching.